Pharma major Ranbaxy Laboratories today said it expects to achieve Rs 14,000 crore (USD 3 billion) in consolidated turnover for the financial year ending December 2012.

As per its medium term plan (MTP) for the period 2010-2012, the company aims to achieve consolidated turnover of USD 3 billion (nearly Rs 14,000 crore) for the financial year ending December 2012, the company said in a filing to the Bombay Stock Exchange.

The company's consolidated total income for the year ended December 31, 2009, increased by 2.82 per cent to Rs 7,890 crore.

India's largest pharmaceutical company, Ranbaxy has a presence in 23 of the top 25 pharmaceutical markets of the world. The company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd, to create a generic pharmaceutical firm. The combined entity now ranks among the top 20 pharmaceutical companies, globally.